Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome
Metformin intake may be related to favorable survival among patients with T2DM and MetSyn. The efficacy might be more remarkable in those with liver, lung, colorectal, and prostate cancers. The potential benefit of metformin in patients with these risk factors should be further investigated.
Authors
- Sang-Hoon Cho (ORCID: https://orcid.org/0000-0003-4884-1477)
- Ji Soo Park (ORCID: https://orcid.org/0000-0002-0522-7736)
- Soo Jin Moon
- Hyung Seok Park (ORCID: https://orcid.org/0000-0003-3526-9977)
Institutions
- Soongsil University (KR)
- Yonsei University (KR)
Publication Details
- Journal
- Preventive Medicine Reports
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1016/j.pmedr.2024.102928
- Citations
- 1
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- National Research Foundation
- Yonsei University
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Yonsei University College of Medicine